The U.S. Food and Drug Administration (FDA) has approved melphalan flufenamide (PEPAXTO®), also known as melflufen, in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory myeloma, who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. Continue reading
Location: Scotland / home based (approx. 10 travel days per year)
Contract: 40 hours per week / permanent
Salary: £25,000 – £27,000 depending on experience
This Research Assistant post supports the research function of Myeloma Patients Europe (MPE). There are two main elements to the job – supporting communication and dissemination of SISAQOL-IMI and to assist with generating patient centred evidence as part of MPE’s newly established Evidence Generation Unit (EGU). The following tasks and core responsibilities are non-exhaustive and subject to change depending on needs of the organisation.
An international multidisciplinary consortium, guided by the European Organisation for Research and Treatment of Cancer (EORTC), has been convened to generate recommendations to standardize the use, analysis, and interpretation of PRO data in cancer clinical trials. Myeloma Patients Europe (MPE) is one of the partners in this project representing the Workgroup or European Cancer Patient Advocacy Networks (WECAN). Continue reading
CARAMBA is a Horizon 2020 project investigating an innovative immunotherapy for the treatment of myeloma called Chimeric Antigen Receptor T-cell (CAR-T) therapy. CAR-T is a form of immunotherapy, which has demonstrated outstanding efficacy against various haematologic malignancies. Continue reading
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the conditional approval for selinexor in combination with dexamethasone for the treatment of adult myeloma patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Continue reading
CAR-T-cell treatment is thought to be one of the most promising therapies in development for the treatment of myeloma. There are several ongoing clinical trials evaluating the safety and efficacy of CAR-T-cells, and some of the studies with very encouraging results. Continue reading
It is with great sadness that we share that our friend, colleague, and fellow patient advocate, Anna Rovira, passed away during the night of the 26 January 2021 after a short but very intense battle against cancer. Continue reading
The Food and Drug Administration (FDA) granted accelerated approval to daratumumab plus hyaluronidase (Darzalex Faspro, Janssen Biotech Inc.), a subcutaneous formulation of daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis. Continue reading
Myeloma Patients Europe (MPE) held a webinar on ASH 2020 myeloma and AL amyloidosis highlights on 16 November to review the most recent myeloma research presented at the annual meeting of the American Society of Hematology (ASH) 2020 (5 – 8 December 2020). Continue reading
Myeloma Patients Europe interviewed Dr Giampaolo Merlini, the Research Director and AL amyloidosis expert from Policlinico San Matteo, University of Pavia, in Italy, to summarise the main highlights on this disease presented at the American Society of Hematology (ASH) Annual Meeting.
Click to hear a summary of the most important studies presented at ASH 2020 and his views on the future of AL amyloidosis treatment.